AbbVie Contract Manufacturing AbbVie Contract Manufacturing

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Emergence Therapeutics","sponsor":"Mablink Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mablink Bioscience and Emergence Therapeutics Enter Into a Licensing Agreement to Develop Antibody Drug Conjugate as a Potential Cancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Emergence Therapeutics","sponsor":"Pontifax Venture Capital","pharmaFlowCategory":"D","amount":"$98.3 million","upfrontCash":"Undisclosed","newsHeadline":"Emergence Therapeutics Raises \u20ac87 million Series A Financing to Advance Nectin-4 ADC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Emergence Therapeutics","sponsor":"Synaffix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$360.0 million","newsHeadline":"Emergence Therapeutics Licenses Synaffix ADC Technology Platform in $360M Deal","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical"},{"orgOrder":0,"company":"Emergence Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Heidelberg Pharma Sells Minority Shareholding in Emergence Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Large molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Emergence Therapeutics

    Menu

    Emergence Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Emergence Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Heidelberg Pharma Sells Minority Shareholding in Emergence Therapeutics

              Details:

              Through the acquisition, Eli gains access to Emergence's ADC pipeline, including ETx-22 (enfortumab vedotin), which targets Nectin-4 and is being developed for bladder, triple-negative breast cancer and malignancies with moderate and low Nectin-4 expression levels.

              Lead Product(s): Enfortumab Vedotin

              Therapeutic Area: Oncology Product Name: ETx-22

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Eli Lilly

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition June 29, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Emergence Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Emergence Therapeutics Licenses Synaffix ADC Technology Platform in $360M Deal

              Details:

              Emergence will be responsible for the research, development, manufacturing and commercialization of the ADCs. Synaffix will be responsible for the manufacturing of components that are specifically related to its proprietary technologies.

              Lead Product(s): Antibody-drug Conjugate

              Therapeutic Area: Technology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Large molecule

              Recipient: Synaffix

              Deal Size: Undisclosed Upfront Cash: $360.0 million

              Deal Type: Licensing Agreement September 06, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Emergence Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Emergence Therapeutics Raises €87 million Series A Financing to Advance Nectin-4 ADC

              Details:

              Proceeds from this funding round will be used to advance the company’s next-generation antibody drug conjugate (ADC) including ETx-22, targeting Nectin-4 to clinical proof-of-concept as well as the development of additional ADC programs.

              Lead Product(s): ETx-22

              Therapeutic Area: Oncology Product Name: ETx-22

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Pontifax Venture Capital

              Deal Size: $98.3 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing December 07, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Emergence Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Mablink Bioscience and Emergence Therapeutics Enter Into a Licensing Agreement to Develop Antibody Drug Conjugate as a Potential Cancer Therapy

              Details:

              Under the terms of the agreement, Emergence Therapeutics will use a PSARlink™ drug-linker developed by Mablink to develop an ADC targeting Nectin-4, a protein overexpressed in several severe cancers.

              Lead Product(s): Antibody-drug Conjugate

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Mablink Bioscience

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement October 21, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Biopharma Group offers CDMO services with expertise in contract R&D for dried products & liquid formulations.
              Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
              Post Enquiry
              POST ENQUIRY